Business Description
![argenx SE argenx SE logo](https://static.gurufocus.com/logos/0C0000AP2X.png?14)
argenx SE
ISIN : US04016X1019
Share Class Description:
ARGX: ADRCompare
Compare
Traded in other countries / regions
ARGX.USAARGX.Belgium0QW0.UKARGX.AustriaARGX.MexicoA1RG34.Brazil1AEA.Germany IPO Date
2017-05-18Description
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 158.99 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 36.72 | |||||
Beneish M-Score | -1.02 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 197.5 | |||||
3-Year EBITDA Growth Rate | 34.3 | |||||
3-Year EPS without NRI Growth Rate | 17.8 | |||||
3-Year FCF Growth Rate | -0.6 | |||||
3-Year Book Growth Rate | 29.9 | |||||
Future 3-5Y EPS without NRI Growth Rate | -231.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 44.5 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 82.65 | |||||
9-Day RSI | 79.04 | |||||
14-Day RSI | 73.97 | |||||
6-1 Month Momentum % | -5.03 | |||||
12-1 Month Momentum % | -3.4 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.75 | |||||
Quick Ratio | 9.01 | |||||
Cash Ratio | 7.52 | |||||
Days Inventory | 633.08 | |||||
Days Sales Outstanding | 83.42 | |||||
Days Payable | 538.57 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.6 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.87 | |||||
Operating Margin % | -29.01 | |||||
Net Margin % | -23.28 | |||||
FCF Margin % | -32.96 | |||||
ROE % | -10.04 | |||||
ROA % | -9.02 | |||||
ROIC % | -48.61 | |||||
ROC (Joel Greenblatt) % | -84.13 | |||||
ROCE % | -9.19 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 18.1 | |||||
PB Ratio | 6.34 | |||||
Price-to-Tangible-Book | 6.54 | |||||
EV-to-EBIT | -77.19 | |||||
EV-to-Forward-EBIT | -82.42 | |||||
EV-to-EBITDA | -77.19 | |||||
EV-to-Forward-EBITDA | -85.43 | |||||
EV-to-Revenue | 16.52 | |||||
EV-to-Forward-Revenue | 12.33 | |||||
EV-to-FCF | -51.19 | |||||
Price-to-Median-PS-Value | 0.41 | |||||
Price-to-Net-Current-Asset-Value | 7.06 | |||||
Price-to-Net-Cash | 9.5 | |||||
Earnings Yield (Greenblatt) % | -1.3 | |||||
FCF Yield % | -1.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
argenx SE Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1,408.177 | ||
EPS (TTM) ($) | -5.67 | ||
Beta | 0.42 | ||
Volatility % | 35.98 | ||
14-Day RSI | 73.97 | ||
14-Day ATR ($) | 11.840478 | ||
20-Day SMA ($) | 394.429 | ||
12-1 Month Momentum % | -3.4 | ||
52-Week Range ($) | 327.725 - 550.76 | ||
Shares Outstanding (Mil) | 59.43 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
argenx SE Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
argenx SE Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
argenx SE Frequently Asked Questions
What is argenx SE(ARGX)'s stock price today?
The current price of ARGX is $430.04. The 52 week high of ARGX is $550.76 and 52 week low is $327.73.
When is next earnings date of argenx SE(ARGX)?
The next earnings date of argenx SE(ARGX) is 2024-07-25.
Does argenx SE(ARGX) pay dividends? If so, how much?
argenx SE(ARGX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |